Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVD275 in Osteoarthritis of the Knee
NCT07338266Phase 1Recruiting
- Sponsor
- Avidence Therapeutics
- Start
- Jan 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of celecoxib in osteoarthritis (OA) (3 arms), sponsored by Avidence Therapeutics. Primary endpoint: Treatment Emergent Adverse Events at 24 weeks. Started Jan 2026; status: recruiting.
02
Drugs
celecoxib
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07338266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07338266.